EC Considers API Regulation In Effort To Fight Counterfeit Drugs
Executive Summary
Stricter requirements for active ingredients, a ban on repackaging, and mandatory company audits of their trading partners are on the table in the European Commission's quest for antidotes to a growing influx of counterfeit medicines
You may also be interested in...
EU Tackles Counterfeits, But Parallel Trade Poses Tough Issues
Tackling counterfeit drugs is one pillar of the European Commission's package of new proposed pharmaceutical legislation. It will mean higher costs for most drug firms, while significant loopholes will remain
EU Tackles Counterfeits, But Parallel Trade Poses Tough Issues
Tackling counterfeit drugs is one pillar of the European Commission's package of new proposed pharmaceutical legislation. It will mean higher costs for most drug firms, while significant loopholes will remain
EU Drug Makers Tackle Traceability With Pharmacy Verification Pilot Project
The European Federation of Pharmaceutical Industries and Associations is spearheading a project to develop an end-to-end verification system for individual packages of medications